Dong M, Feng FY. Clinical application of bisphosphonates in treatment of bone metastases[J]. Oncology Progess, 2008, 6(1): 6-10.
[2]
Philippe Clezardin, Frank HE, Pierrick GJF. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity[J]. Cancer Research, 2005, 65(12) : 4 971-4 974.
[3]
Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases[J]. Journal Clinical Oncology, 2005, 23(32): 8 219-8 224.
[4]
Reid IR. Bisphosphonates: new indications andmethods of administration[J]. Current Opinion in Rheumatology, 2003, 15(4): 458-463.
Chen CQ, Luo SN, Lin JG, et al. Preparation and biodistribution of 99Tcm-PIDP as bone imaging agent[J]. Nuclear Science and Techniques, 2009, 20(5): 302-306.
[11]
Makbule A, Funda GD. The rabbit biodistribution of a therapeutic dose of zoledronic acid labeled with 99Tcm[J]. Applied Radiation and Isotopes, 2009, 67: 1 616-1 621.
[12]
Lin JG, Luo SN, Chen CQ, et al. Preparation and preclinical pharmacological study on a novel bone imaging agent 99Tcm-EMIDP[J]. Applied Radiation and Isotopes, 2010, 68(9): 1 616-1 622.
[13]
El-Mabhouh AA, Angelov CA. A 99Tcm-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer[J]. Nuclear Medicine and Biology, 2006， 33: 715-722.
